Anika Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SCHEDULE 13D/A: Caligan Partners Amends Anika Therapeutics Stake Disclosure
Caligan Partners LP updated its Schedule 13D filing for Anika Therapeutics, Inc., detailing derivative agreements representing 4.3% economic exposure.
NASDAQ
Caligan Partners LP and David Johnson updated their beneficial ownership in Anika Therapeutics, Inc., maintaining a 9.95% stake and disclosing cash-settled derivative agreements.